SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial
SELLAS Life Sciences Group (NASDAQ:SLS) announced on Thursday promising mid-stage trial results for SLS009, a highly ...
Nature6y
Obinutuzumab for the treatment of non-Hodgkin lymphomas
F. Hoffmann-La Roche Ltd (Roche) has a rich history of antibody therapies to treat cancers (malignancies) that affect B cells (a type of white blood cell), including non-Hodgkin lymphoma and ...
Hosted on MSN2d
InnoCare Pharma receives approval for CLL/SLL combination therapy trial in China
China's National Medical Products Administration has approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) ...
Cure Today7d
Breyanzi Improves Responses in R/R Indolent B-Cell Non-Hodgkin Lymphoma
Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...
The American Journal of Managed Care14d
Refining Remission Assessment in Aggressive B-Cell Lymphomas
Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma ... is the first step toward a cure in treating aggressive B-cell lymphomas ...
Nature6y
Non-Hodgkin lymphoma: Treatment advances for diffuse large B-cell lymphoma
Others are faster growing ('aggressive'), for example, diffuse large B-cell lymphoma, Burkitt’s lymphoma ... for these patients (around 60% will be cured), still approximately 30—40% of ...